S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
NYSE:AIM

AIM ImmunoTech (AIM) Stock Forecast, Price & News

$0.44
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.43
$0.46
50-Day Range
$0.40
$0.54
52-Week Range
$0.29
$1.05
Volume
82,152 shs
Average Volume
64,258 shs
Market Capitalization
$21.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AIM stock logo

About AIM ImmunoTech (NYSE:AIM) Stock

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

AIM Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Earnings Preview: AIM ImmunoTech
AIM ImmunoTech (AIM) Scheduled to Post Earnings on Tuesday
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Ascendiant Remains a Buy on AIM ImmunoTech (AIM)
Maxim Group Sticks to Their Buy Rating for AIM ImmunoTech (AIM)
AIM ImmunoTech Earnings Preview
AIM ImmunoTech (NYSE:AIM) Trading Down 4.2%
AIM ImmunoTech to Participate in Solve M.E.
See More Headlines

AIM Price History

AIM Company Calendar

Last Earnings
4/03/2023
Today
6/04/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Employees
21
Year Founded
1990

Profitability

Net Income
$-19,440,000.00
Net Margins
-12,362.82%
Pretax Margin
-12,362.82%

Debt

Sales & Book Value

Annual Sales
$157,000.00
Book Value
$0.71 per share

Miscellaneous

Free Float
48,398,000
Market Cap
$21.54 million
Optionable
Not Optionable
Beta
-0.30

Social Links


Key Executives

  • Thomas Kenwood Equels
    Executive Vice Chairman, President & CEO
  • Peter W. Rodino
    COO, Secretary & General Counsel
  • Robert Dickey
    Chief Financial Officer
  • David R. Strayer
    Chief Medical Officer
  • Christopher McAleer
    Chief Scientific Officer













AIM Stock - Frequently Asked Questions

How have AIM shares performed in 2023?

AIM ImmunoTech's stock was trading at $0.3119 at the beginning of the year. Since then, AIM stock has increased by 42.7% and is now trading at $0.4450.
View the best growth stocks for 2023 here
.

When is AIM ImmunoTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our AIM earnings forecast
.

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) released its quarterly earnings data on Monday, April, 3rd. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.06 million for the quarter. AIM ImmunoTech had a negative net margin of 12,362.82% and a negative trailing twelve-month return on equity of 47.58%.

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX).

What is AIM ImmunoTech's stock symbol?

AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."

Who are AIM ImmunoTech's major shareholders?

AIM ImmunoTech's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.35%). Insiders that own company stock include Stewart Appelrouth, Thomas K Equels and Thomas K Equels.
View institutional ownership trends
.

How do I buy shares of AIM ImmunoTech?

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AIM ImmunoTech's stock price today?

One share of AIM stock can currently be purchased for approximately $0.45.

How much money does AIM ImmunoTech make?

AIM ImmunoTech (NYSE:AIM) has a market capitalization of $21.54 million and generates $157,000.00 in revenue each year. The company earns $-19,440,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How can I contact AIM ImmunoTech?

AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The official website for the company is aimimmuno.com. The company can be reached via phone at (352) 448-7797, via email at ir@aimimmuno.com, or via fax at 215-988-1739.

This page (NYSE:AIM) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -